T cell engineering has changed the landscape of cancer immunotherapy. Chimeric antigen
receptor T cells have demonstrated a remarkable efficacy in the treatment of B cell …

The approval of the first immune checkpoint inhibitors provided a paradigm shift for the
treatment of malignancies across a broad range of indications. Whereas initially, single …

Background Tebentafusp, a T-cell receptor–bispecific molecule that targets glycoprotein 100
and CD3, is approved for adult patients who are positive for HLA-A* 02: 01 and have …

Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …

The gut microbiota have long been recognized to play a key role in human health and
disease. Currently, several lines of evidence from preclinical to clinical research have …

Monoclonal antibodies are a growing class of targeted cancer therapeutics, characterized by
exquisite specificity, long serum half-life, high affinity and immune effector functions. In this …

The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …

Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However,
resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the …

Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine
kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung …

Melanomas arising in the uveal tract of the eye are a rare form of the disease with a biology
and clinical phenotype distinct from their more common cutaneous counterparts. Treatment …